Home / Library / The tirzepatide prior authorization playbook

Access · how approvals are actually won

The tirzepatide prior authorization playbook

Published 2026-08-14 · 8 min read · By the research team · pending clinician sign-off

What the criteria really ask for, translated from insurer-speak

Pull your plan's actual PA criteria — searchable as "[insurer] Zepbound prior authorization criteria PDF," and worth ten minutes because plans vary meaningfully. The recurring elements: BMI thresholds with a dated chart measurement (a home scale doesn't count; a visit weight does); comorbidity by coded diagnosis — which is why the pre-application move is a records review, and why an unmeasured A1c or an unstudied snore is a qualification lying on the table (prediabetes at 5.7%+ and sleep-study-confirmed OSA are the two most commonly missing pieces); lifestyle-attempt documentation, satisfiable by a clinician's note describing months of guided effort — the tip being that a primary-care note written today summarizing the last year's real attempts often satisfies a requirement people assume needs a formal program; and sometimes step therapy, increasingly waived for GLP-1s and contestable with a medical-necessity letter when clinically inappropriate. Your prescriber's office files the PA; your job is making their file complete on the first pass, because incomplete-info denials are the most common and most preventable kind.

The three doors, and choosing the right one

The weight-management door (Zepbound for obesity) is the most restricted — a minority of commercial plans cover it, Medicare's exclusion holds outside the Bridge, and criteria are enforced strictly. The OSA door changed the game quietly: Zepbound's sleep-apnea indication means moderate-to-severe OSA with obesity is a medical claim many plans handle far more generously — a sleep study is the key, home studies count, and the OSA guide walks the route; if you snore, stop breathing at night per a partner, or wake unrefreshed, the study may be the highest-yield step in this entire article. The diabetes door (Mounjaro for T2D) approves most readily of all — but requires actual type 2 diabetes; prediabetes doesn't open it, and misrepresenting a diagnosis is fraud, full stop. The strategy is honest door-matching: apply under the strongest indication you genuinely hold, with Medicare beneficiaries routing first through the Bridge and its prescriber-submitted process.

The denial-and-appeal ladder, with clocks

A denial letter must state its reason — read it, because the reason picks your counter. "Criteria not met / information missing": fix the file and resubmit; this is administrative, not medical. "Not medically necessary": the prescriber files a first-level appeal with a letter of medical necessity — the strong template covers BMI trajectory, comorbidities and their progression, prior attempts and outcomes, and the clinical case for this agent specifically (the head-to-head efficacy data earns its citation here). Plans must decide standard appeals on fixed timelines — commonly around 30 days, faster for expedited requests when health is at risk. Still denied: second-level internal appeal, often before a different reviewer, then external review — an independent process most commercial plans must offer, which overturns insurers at meaningful rates and costs you a form. Persistence is the underused drug here: a large share of ultimately-approved GLP-1 patients were denied at least once, and every level has a deadline printed in your denial letter — calendar it the day the letter arrives. Meanwhile, bridge the gap: LillyDirect self-pay or a verified compounded program per the cash ladder keeps treatment moving, and a denied PA plus months of self-funded, documented progress is itself persuasive appeal evidence.

Renewals and the quiet second gate

Approval isn't permanent — most PAs last six to twelve months, and renewal criteria typically demand demonstrated response: commonly ≥5% loss from baseline, adherence, and continued medical need. The implications: get your baseline weight in the chart at start (renewal math needs an anchor), keep visits on schedule so response is documented contemporaneously, and know that a plateau after strong initial loss is defensible with a good letter — maintenance of a 15% loss is therapeutic success, and prescribers make that argument routinely — while quiet non-adherence is not. Plan-year turnover is the other trap: formularies change each January, a covered drug can move tiers or drop, and open enrollment is when to check next year's formulary before you're mid-treatment on a plan that abandoned it. The whole apparatus rewards exactly one trait — documentation discipline — which is cheap, boring, and worth thousands of dollars a year.

The medical-necessity letter, annotated paragraph by paragraph

The appeal letter is a genre with a working structure, and knowing it lets you help your prescriber's office assemble a strong one fast. Paragraph one — the patient and the ask: name, plan, the specific drug and dose requested, and the indication in the plan's own criteria language; letters that mirror the criteria document get approved by reviewers who are checking boxes against it. Paragraph two — the clinical picture: BMI with dates and trajectory, each qualifying comorbidity with diagnosis dates and current management — this is where your documentation kit's contents become sentences. Paragraph three — the history of adequate trial: lifestyle attempts with durations and outcomes, any prior medications tried and why they failed or were inappropriate, which answers step-therapy objections before they're raised. Paragraph four — why this agent: the head-to-head efficacy data (SURMOUNT-5's 20.2% vs 13.7%), indication-specific evidence (the OSA data if that's your door), and any patient-specific factors making alternatives unsuitable. Paragraph five — the stakes: the trajectory without treatment, stated clinically. Your role in this isn't authorship — it's logistics: deliver the kit, offer the attempts narrative in writing, and ask the office whether they use a template (most do; the good ones customize paragraph four). A complete letter takes a practiced office twenty minutes with your inputs and days without them, and the difference is usually the difference in the outcome.

The employer channel: changing the answer instead of appealing it

When the plan simply excludes weight-management drugs, appeals hit a wall — but exclusions are choices employers revisit annually, and employees are allowed to be inputs. The mechanics: most large employers self-insure, meaning the company itself decides the formulary its administrator runs, and benefits teams weigh exactly two currencies — cost projections and employee demand. Your levers, in ascending effort: the one-email version to HR/benefits ("Is GLP-1 coverage for weight management under consideration for next plan year? I'd like to register interest and can share my experience navigating the exclusion") — individually small, and benefits teams genuinely tally these; the open-enrollment-comment version, timed to when decisions are actually being made (decisions for January typically firm up the prior summer and fall); and the organized version, where an employee resource group or several colleagues raise it together with the growing employer-ROI literature on obesity treatment — the argument benefits consultants are already bringing them from the other side. Manage expectations honestly: this is a next-plan-year play, not a this-prescription play, and the cash-bridge strategies from the cost guide carry the interim. But of every route in this article, it's the only one that fixes the problem for your colleagues too — and denied-in-writing employees asking politely at scale is precisely how the coverage map's "roughly a third" has been inching upward.

Working the pharmacy counter: the adjudication layer

Between approval and medication sits a layer with its own failure modes, worth knowing because they masquerade as denials. The test claim: before assuming anything about coverage, have a pharmacy run the prescription — the rejection codes that come back ("PA required," "not on formulary," "quantity limit," "plan exclusion") are the plan's real position in real time, and each routes differently: PA-required goes to the playbook above; quantity-limit issues (plans sometimes balk at dose-pack logistics) resolve with a pharmacist-to-plan call or a prescriber note; not-on-formulary invites the formulary-exception request, a cousin of the PA your prescriber files arguing for off-formulary coverage. Post-approval friction has its own list: approvals tied to a specific pharmacy network (transfer rather than re-fight), the KwikPen-versus-vial specificity that Bridge users know well, and the annual reauthorization lapse that surfaces as a surprise counter rejection in month thirteen — preventable with the calendar entry this guide keeps prescribing. The pharmacist is the under-used ally in all of it: they see plan behavior across hundreds of patients, they can often name which local plans approve what, and thirty seconds of "what's this rejection code actually mean" routinely saves a week of guessing. The counter isn't where coverage is won — but it's where won coverage gets lost to logistics, and logistics is the cheapest thing in this article to be good at.

The 2026 landscape shifts your application should anticipate

PA strategy ages fast, so aim at where the puck is going. The pressure toward coverage is real and compounding: SELECT-class outcomes data keeps converting "lifestyle drug" framing into "cardiometabolic therapy" framing, the OSA indication opened a medical door plans are still learning to process consistently, and negotiated pricing (semaglutide's ~$274 Part D price landing in 2027) changes the payer math that drove exclusions. The counter-pressure is fiscal: GLP-1 spend is the line item every benefits consultant flags, producing the tightened utilization management you're navigating — stricter documentation, renewal response requirements, and the occasional plan retreating from coverage it briefly offered. Application-level translations: build every file to the strictest current standard (it survives plan changes), anchor renewals in documented response from day one, treat each January as a re-verification event rather than a formality, and if you're choosing between plans at open enrollment, weight the formulary check as heavily as the premium — a plan that covers your $1,000/month medication at a $50 copay is worth a substantial premium difference, which is arithmetic almost nobody runs until year two. The meta-lesson of the whole playbook holds at the landscape level too: this system rewards the documented, the persistent, and the early — and punishes improvisation at every gate.

FAQ

How long does tirzepatide prior authorization take?

Initial PA decisions commonly return within days to two weeks once the prescriber submits complete documentation. Incomplete files are the main cause of delay — and of preventable denials.

What do I do if my Zepbound prior authorization is denied?

Read the denial reason, then fix or appeal accordingly: resubmit for missing-info denials, file a medical-necessity appeal for the rest. Appeals run through internal levels to independent external review on fixed timelines, and overturn rates are meaningful.

Does a sleep apnea diagnosis make Zepbound easier to get covered?

Often, yes — Zepbound's OSA indication turns moderate-to-severe sleep apnea with obesity into a medical claim many plans treat more generously than weight management. A sleep study is the qualifying document.

Related: Insurance coverage map 2026 · The OSA coverage door · Medicare Bridge mechanics · Cash routes while you appeal

Educational content, not medical advice — dosing, switching, and side-effect decisions belong with your prescriber. Sources and trial citations: the source library. Corrections within 48 hours: policy.